𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Temporal trends in the proportion cured for cancer of the colon and rectum: A population-based study using data from the Finnish Cancer Registry

✍ Scribed by Paul C. Lambert; Paul W. Dickman; Pia Österlund; Therese Andersson; Risto Sankila; Bengt Glimelius


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
418 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Colorectal cancer is the third most common cancer worldwide and the second most common cancer in Europe. Cumulative relative survival curves for both cancer of the colon and cancer of the rectum generally plateau after ∼6–8 years. When this occurs, “population” or “statistical” cure is reached. We analyzed data from the Finnish Cancer Registry over a 50‐year period using methods that simultaneously estimate the proportion of patients cured of disease (the cure fraction) and the survival time distribution of the “uncured” group. Our primary aim was to investigate temporal trends in the cure fraction and median survival of the uncured by age group for both cancer of the colon and rectum. For both cancers, the cure fraction has increased dramatically over time for all age groups. However, the difference in the cure fraction between age groups has reduced over time, particularly for cancer of the colon. Median survival in the uncured has also increased over time in all age groups but there still remains an inverse relationship between age and median survival, with shorter median survival with increasing age. The reasons for these impressive increases in patient survival are complex, but are highly likely to be strongly related to many improvements in cancer care over this same time period. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Prognostic factors for survival of stage
✍ S.-H. Ignatius Ou; Jason A. Zell; Argyrios Ziogas; Hoda Anton-Culver 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## BACKGROUND. Platinum‐based adjuvant chemotherapy in randomized trials has failed to provide a survival benefit in patients with resected stage I nonsmall cell lung cancer (NSCLC). Using data from the California Cancer Registry (CCR), we explored factors that had detrimental effects